These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 32598639)

  • 1. [Diabetes mellitus and chronic liver diseases. Part 1: general mechanisms of etiology and pathogenesis].
    Kalmykova ZA; Kononenko IV; Mayorov AY
    Ter Arkh; 2019 Oct; 91(10):106-111. PubMed ID: 32598639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Diabetes mellitus and chronic liver diseases. Literature review (part 2): treatment features].
    Kalmykova ZA; Kononenko IV; Mayorov AY
    Ter Arkh; 2019 Dec; 91(12):115-121. PubMed ID: 32598598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diabetes in chronic liver disease: from old concepts to new evidence.
    Picardi A; D'Avola D; Gentilucci UV; Galati G; Fiori E; Spataro S; Afeltra A
    Diabetes Metab Res Rev; 2006; 22(4):274-83. PubMed ID: 16506276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diabetes co-existing with chronic liver disease: clinical features and response to therapy.
    Chuhwak EK; Pam SD
    Niger J Med; 2007; 16(2):156-60. PubMed ID: 17694770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Managing diabetes in patients with chronic liver disease.
    Khan R; Foster GR; Chowdhury TA
    Postgrad Med; 2012 Jul; 124(4):130-7. PubMed ID: 22913901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bezafibrate ameliorates diabetes via reduced steatosis and improved hepatic insulin sensitivity in diabetic TallyHo mice.
    Franko A; Neschen S; Rozman J; Rathkolb B; Aichler M; Feuchtinger A; Brachthäuser L; Neff F; Kovarova M; Wolf E; Fuchs H; Häring HU; Peter A; Hrabě de Angelis M
    Mol Metab; 2017 Mar; 6(3):256-266. PubMed ID: 28271032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatogenous diabetes. Current views of an ancient problem.
    García-Compean D; Jaquez-Quintana JO; Maldonado-Garza H
    Ann Hepatol; 2009; 8(1):13-20. PubMed ID: 19221528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Role of the liver in the regulation of glucose metabolism in diabetes and chronic liver disease].
    Cotrozzi G; Casini Raggi V; Relli P; Buzzelli G
    Ann Ital Med Int; 1997; 12(2):84-91. PubMed ID: 9333317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Managing diabetes and liver disease association.
    Hamed AE; Elsahar M; Elwan NM; El-Nakeep S; Naguib M; Soliman HH; Ahmed Aboubakr A; AbdelMaqsod A; Sedrak H; Assaad SN; Elwakil R; Esmat G; Salh S; Mostafa T; Mogawer S; Sadek SE; Saber MM; Ezelarab H; Mahmoud AA; Sultan S; El Kassas M; Kamal E; ElSayed NM; Moussa S
    Arab J Gastroenterol; 2018 Dec; 19(4):166-179. PubMed ID: 30420265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liver disease and diabetes mellitus.
    Baig NA; Herrine SK; Rubin R
    Clin Lab Med; 2001 Mar; 21(1):193-207. PubMed ID: 11321935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities.
    Resmini E; Minuto F; Colao A; Ferone D
    Acta Diabetol; 2009 Jun; 46(2):85-95. PubMed ID: 19322513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The ratio of insulin-like growth factor-I/insulin-like growth factor-binding protein-3 in sera of patients with hepatitis C virus-related chronic liver disease as a predictive marker of insulin resistance.
    Himoto T; Tani J; Miyoshi H; Yoneyama H; Mori H; Inukai M; Masugata H; Goda F; Senda S; Haba R; Masaki T
    Nutr Res; 2013 Jan; 33(1):27-33. PubMed ID: 23351407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis C virus, diabetes and steatosis: clinical evidence in favor of a linkage and role of genotypes.
    Mihm S
    Dig Dis; 2010; 28(1):280-4. PubMed ID: 20460924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-diabetes effect of chronic intermittent hypobaric hypoxia through improving liver insulin resistance in diabetic rats.
    Tian YM; Liu Y; Wang S; Dong Y; Su T; Ma HJ; Zhang Y
    Life Sci; 2016 Apr; 150():1-7. PubMed ID: 26883978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dorothy Hodgkin Lecture 2012: non-alcoholic fatty liver disease, insulin resistance and ectopic fat: a new problem in diabetes management.
    Byrne CD
    Diabet Med; 2012 Sep; 29(9):1098-107. PubMed ID: 22672330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Non-alcoholic fatty liver disease in dyslipidemia and insulin resistance: similarities and differences; differential approach to therapy].
    Lazebnik LB; Zvenigorodskaia LA; Egorova EG; Mel'nikova NV; Khomeriki SG
    Eksp Klin Gastroenterol; 2009; (8):4-11. PubMed ID: 20469672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liver cirrhosis and diabetes: risk factors, pathophysiology, clinical implications and management.
    Garcia-Compean D; Jaquez-Quintana JO; Gonzalez-Gonzalez JA; Maldonado-Garza H
    World J Gastroenterol; 2009 Jan; 15(3):280-8. PubMed ID: 19140227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatogenous diabetes: Is it a neglected condition in chronic liver disease?
    García-Compeán D; González-González JA; Lavalle-González FJ; González-Moreno EI; Villarreal-Pérez JZ; Maldonado-Garza HJ
    World J Gastroenterol; 2016 Mar; 22(10):2869-74. PubMed ID: 26973383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of incretin hormones and glucagon in patients with liver disease.
    Junker AE
    Dan Med J; 2017 May; 64(5):. PubMed ID: 28552096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Diabetes mellitus secondary to liver diseases. A review (author's transl)].
    Guillon J; Charbonnel B
    Diabete Metab; 1975 Sep; 1(3):191-9. PubMed ID: 791727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.